GabonTuberculosis profile
Population  2016 2 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.5 (0.96–2.2) 76 (49–110)
Mortality (HIV+TB only) 0.76 (0.51–1) 38 (26–53)
Incidence  (includes HIV+TB) 9.6 (6.9–13) 485 (347–646)
Incidence (HIV+TB only) 2 (1.4–2.8) 102 (70–139)
Incidence (MDR/RR-TB)** 0.4 (0.29–0.5) 20 (15–25)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.57 (0.4–0.75) 3.4 (2.3–4.4) 3.9 (2.7–5.1)
Males 0.65 (0.45–0.85) 5 (3.5–6.6) 5.7 (3.9–7.4)
Total 1.2 (0.85–1.6) 8.4 (5.8–11) 9.6 (6.9–13)
TB case notifications, 2016  
Total cases notified 6 036
Total new and relapse 5 567
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 54%
          - % pulmonary 92%
          - % bacteriologically confirmed among pulmonary 47%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 58% (44–81)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.24 (0.15–0.35)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 635 21%
          - on antiretroviral therapy 332 52%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  230
(190–270)
Estimated % of TB cases with MDR/RR-TB 2.8% (2.1–3.4) 13% (8.9–17)  
% notified tested for rifampicin resistance 12% <1% 639
MDR/RR-TB cases tested for resistance to second-line drugs   30
Laboratory-confirmed cases MDR/RR-TB: 30, XDR-TB:
Patients started on treatment **** MDR/RR-TB: 13, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 50% 5 727
Previously treated cases, excluding relapse, registered in 2015 48% 566
HIV-positive TB cases registered in 2015    
MDR/RR-TB cases started on second-line treatment in 2014    
XDR-TB cases started on second-line treatment in 2014    
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2017  
National TB budget (US$ millions) 2.6
Funding source: 7% domestic, 85% international, 8% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-01-16 Data: www.who.int/tb/data